Denali Advisors LLC Purchases Shares of 32,600 RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Denali Advisors LLC acquired a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the 1st quarter, Holdings Channel reports. The fund acquired 32,600 shares of the company’s stock, valued at approximately $293,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its position in RAPT Therapeutics by 347.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,981 shares of the company’s stock worth $99,000 after buying an additional 3,092 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of RAPT Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 7,190 shares of the company’s stock valued at $179,000 after acquiring an additional 1,824 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of RAPT Therapeutics during the 4th quarter worth about $233,000. SG Americas Securities LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter worth approximately $244,000. Finally, Chesapeake Capital Corp IL purchased a new stake in RAPT Therapeutics in the fourth quarter valued at approximately $254,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Stock Performance

NASDAQ RAPT opened at $2.72 on Thursday. RAPT Therapeutics, Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $27.35. The business has a 50 day moving average price of $4.60 and a two-hundred day moving average price of $12.28.

RAPT Therapeutics (NASDAQ:RAPT) last announced its earnings results on Thursday, May 9th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01). As a group, sell-side analysts forecast that RAPT Therapeutics, Inc. will post -2.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on RAPT. Guggenheim downgraded RAPT Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 10th. Wolfe Research restated a “peer perform” rating on shares of RAPT Therapeutics in a research note on Tuesday, May 14th. Barclays lowered RAPT Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $13.00 to $4.00 in a research note on Friday, May 10th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research report on Wednesday, April 10th. Finally, JPMorgan Chase & Co. cut their price target on shares of RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, RAPT Therapeutics presently has an average rating of “Hold” and a consensus price target of $24.67.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.